- The disease
- Diabetic foot ulcers (DFUs) are open sores or wounds that develop on the feet of people with diabetes, arising from a combination of poor circulation, nerve damage, and impaired immune response. They are a leading cause of non-traumatic lower-limb amputation globally. Standard care includes wound debridement, offloading pressure, infection control, and dressings, but healing rates remain low and recurrence is common. A significant proportion of patients do not respond adequately to existing treatments.
- What the asset is trying to do
- CYP-006TK consists of Cymerus mesenchymal stem cells (MSCs), which are allogeneic (derived from a donor rather than the patient) and manufactured from induced pluripotent stem cells (iPSCs) using Cynata's proprietary Cymerus process. MSCs are not believed to permanently engraft or replace tissue; instead, they are thought to act through transient anti-inflammatory and tissue-repair signalling. The iPSC starting point is intended to allow production of large, consistent batches from a single donor cell line, distinguishing the manufacturing process from conventional bone-marrow-derived MSC products that require multiple donors.
- What the trial is measuring, and why it matters
- The completed Phase 1 trial (NCT05165628) assessed the safety, tolerability, and efficacy of CYP-006TK in adults with DFUs (per ClinicalTrials.gov NCT05165628). Safety and tolerability are the primary focus of Phase 1 studies; efficacy measures such as wound closure or reduction in ulcer area are typically collected as exploratory endpoints to inform later-phase design. The trial enrolled up to 30 participants and reached its primary completion date of 24 September 2024 (per ClinicalTrials.gov NCT05165628).
- Efficacy benchmarks in this setting
- No MSC product is currently approved specifically for diabetic foot ulcers. Among approved wound-care biologics in DFUs, becaplermin gel (Regranex) achieved complete wound closure rates of approximately 50% versus approximately 35% for placebo in pivotal trials (per FDA prescribing information for Regranex). The only FDA-approved MSC product to date is remestemcel-L (Ryoncil, Mesoblast), cleared in December 2024 for paediatric steroid-refractory acute graft-versus-host disease (GvHD), a different indication entirely (per Ryoncil US prescribing information). Early-stage figures from single-arm or small Phase 1 cohorts are not statistically comparable to randomised controlled trial results from approved products, and no direct comparison between CYP-006TK and any approved therapy can be drawn from Phase 1 data.